| Lu, Fang |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
| Wu, Yu M |
NCT05219617 / 2022-001256-42: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults |
|
|
| Recruiting | 3 | 252 | Europe, US, RoW | Carisbamate | SK Life Science, Inc., SK Life Science, Inc | Seizures, Lennox Gastaut Syndrome | 06/25 | 06/26 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
TQB2618- I -02, NCT05426798: Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes |
|
|
| Recruiting | 1 | 73 | RoW | TQB2618 injection azacitidine, AZA decitabine, DAC | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes | 09/23 | 12/23 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
| Wang, Long |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
| Xu, Hao |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
| Yu, Renhuan |
NCT06006689: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) |
|
|
| Recruiting | 2 | 228 | RoW | Qishen Yiqi Dripping Pills placebo 3 bags, Placebo group, Low dose Qishen Yiqi Dripping Pills 3 bags, Low dose group, High dose Qishen Yiqi Dripping Pills 3 bags, High dose group | Tasly Pharmaceutical Group Co., Ltd | Diabetic Kidney Disease | 09/25 | 09/25 | | |
| Wang, Anlu |
| No trials found |
